ADVM Insider Trading
Adverum Biotechnologies, Inc. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Adverum Biotechnologies, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-09 05:45 | 2025-12-05 | Fischer Laurent | Director, Officer - CEO, PRESIDENT AND DIRECTOR | BUY | $4.30 | 128,699 | $553,920 | 201,513 | +176.8% |
| 2025-12-09 05:45 | 2025-12-05 | Soparkar Peter | Officer - CHIEF OPERATING OFFICER | BUY | $4.22 | 50,000 | $211,000 | 80,189 | +165.6% |
| 2025-12-06 02:20 | 2025-12-04 | Leonard Braden Michael | 10% owner | SELL | $4.19 | 524,560 | $2,200,372 | 1,958,080 | -21.1% |
| 2025-12-04 05:39 | 2025-12-01 | Leonard Braden Michael | 10% owner | SELL | $4.19 | 574,886 | $2,407,853 | 2,428,640 | -19.1% |
| 2025-05-16 23:46 | 2025-05-15 | Soparkar Peter | Officer - CHIEF OPERATING OFFICER | SELL | $2.00 | 2,960 | $5,920 | 39,154 | -7.0% |
| 2025-05-16 23:45 | 2025-05-15 | Seyedkazemi Setareh | Officer - CHIEF DEVELOPMENT OFFICER | SELL | $2.00 | 924 | $1,848 | 13,768 | -6.3% |
| 2025-05-16 23:44 | 2025-05-15 | Fischer Laurent | Director, Officer - CEO, PRESIDENT AND DIRECTOR | SELL | $2.00 | 9,126 | $18,252 | 87,488 | -9.4% |
| 2025-04-24 16:35 | 2025-04-22 | Leonard Braden Michael | 10% owner | BUY | $3.00 | 350,000 | $1,048,950 | 191,800 | +100.0% |
| 2025-04-03 01:07 | 2025-03-31 | Leonard Braden Michael | 10% owner | BUY | $4.23 | 34,775 | $147,074 | 2,757,526 | +1.3% |
| 2025-03-28 02:06 | 2025-03-26 | Leonard Braden Michael | 10% owner | BUY | $5.11 | 37,000 | $188,929 | 141,800 | +35.3% |
| 2025-03-21 03:02 | 2025-03-18 | Leonard Braden Michael | 10% owner | BUY | $4.98 | 117,941 | $587,570 | 2,722,761 | +4.5% |
| 2025-03-01 00:04 | 2025-02-26 | Leonard Braden Michael | 10% owner | BUY | $4.27 | 336,756 | $1,439,093 | 2,604,820 | +14.8% |
| 2024-07-31 23:19 | 2024-07-30 | Leonard Braden Michael | 10% owner | BUY | $7.15 | 85,800 | $613,470 | 2,268,064 | +3.9% |
| 2024-07-19 04:16 | 2024-07-17 | Leonard Braden Michael | 10% owner | BUY | $8.26 | 216,264 | $1,785,670 | 2,182,264 | +11.0% |
| 2024-02-10 01:51 | 2024-02-07 | Scopa James Paul | Director | BUY | $1.35 | 100,000 | $135,000 | 100,000 | +100.0% |
| 2024-02-10 01:50 | 2024-02-07 | Lupher, Jr. Mark L. | Director | BUY | $1.35 | 130,000 | $175,500 | 130,000 | +100.0% |
| 2023-09-19 01:54 | 2023-09-15 | Seyedkazemi Setareh | Officer - Chief Development Officer | SELL | $1.52 | 6,201 | $9,429 | 47,674 | -11.5% |
| 2023-06-09 23:26 | 2023-06-07 | Rubinstein Linda M | Officer - Chief Financial Officer | BUY | $1.45 | 100,000 | $145,490 | 100,000 | +100.0% |
| 2023-03-18 01:02 | 2023-03-15 | Riley Brigit | Officer - Chief Scientific Officer | SELL | $0.78 | 7,299 | $5,705 | 117,435 | -5.9% |
| 2023-03-18 01:02 | 2023-03-15 | Soparkar Peter | Officer - Chief Operating Officer | SELL | $0.78 | 13,360 | $10,442 | 265,891 | -4.8% |
| 2023-03-18 01:01 | 2023-03-15 | Fischer Laurent | Director, Officer - CEO, President and Director | SELL | $0.78 | 41,239 | $32,232 | 692,141 | -5.6% |
| 2022-09-22 03:01 | 2022-09-19 | Beckman Richard | Officer - Chief Medical Officer | SELL | $1.07 | 4,272 | $4,570 | 39,061 | -9.9% |
| 2022-09-22 03:00 | 2022-09-19 | Seyedkazemi Setareh | Officer - Chief Development Officer | SELL | $1.07 | 6,058 | $6,480 | 47,875 | -11.2% |
| 2022-09-22 02:59 | 2022-09-19 | Soparkar Peter | Officer - See Remarks section | SELL | $1.07 | 13,305 | $14,232 | 273,251 | -4.6% |
| 2022-09-22 02:58 | 2022-09-19 | Riley Brigit | Officer - Chief Scientific Officer | SELL | $1.07 | 7,266 | $7,772 | 118,734 | -5.8% |
| 2022-09-22 02:57 | 2022-09-19 | Fischer Laurent | Director, Officer - CEO, President and Director | SELL | $1.07 | 41,082 | $43,941 | 727,380 | -5.3% |
| 2022-05-24 23:47 | 2022-05-23 | Seyedkazemi Setareh | Officer - Chief Development Officer | BUY | $0.84 | 20,000 | $16,800 | 20,600 | +3,333.3% |
| 2022-05-20 02:43 | 2022-05-17 | Beckman Richard | Officer - Chief Medical Officer | BUY | $0.82 | 10,000 | $8,228 | 10,000 | +100.0% |
| 2022-05-18 23:43 | 2022-05-16 | Svoronos Dawn | Director | BUY | $0.85 | 30,000 | $25,578 | 50,000 | +150.0% |
| 2022-05-18 01:28 | 2022-05-13 | D'Souza Rupert | Officer - Chief Financial Officer | BUY | $0.84 | 20,000 | $16,856 | 20,850 | +2,352.9% |
| 2022-04-23 00:00 | 2022-04-20 | Fischer Laurent | Director, Officer - CEO, President and Director | BUY | $1.11 | 25,000 | $27,800 | 762,462 | +3.4% |
| 2022-04-20 23:35 | 2022-04-19 | Soparkar Peter | Officer - See Remarks section | BUY | $1.14 | 21,925 | $24,995 | 280,556 | +8.5% |
| 2021-12-11 01:26 | 2021-12-08 | Fischer Laurent | Director, Officer - CEO, President and Director | BUY | $1.82 | 25,000 | $45,610 | 737,462 | +3.5% |
| 2021-12-11 01:26 | 2021-12-08 | Soparkar Peter | Officer - See Remarks section | BUY | $1.91 | 25,000 | $47,750 | 258,631 | +10.7% |
| 2021-11-18 00:38 | 2021-11-15 | Scopa James Paul | Director | SELL | $2.18 | 50,000 | $109,000 | 3,334 | -93.7% |
| 2021-10-05 00:36 | 2021-09-30 | Clark Julie | Officer - Chief Medical Officer | SELL | $2.17 | 4,766 | $10,342 | 164,723 | -2.8% |
| 2021-04-02 03:21 | 2021-03-31 | Svoronos Dawn | Director | BUY | $10.02 | 20,000 | $200,338 | 20,000 | +100.0% |
| 2021-03-25 02:47 | 2021-03-24 | Fischer Laurent | Director, Officer - CEO and Director | BUY | $9.88 | 10,000 | $98,780 | 26,292 | +61.4% |
| 2021-03-25 02:46 | 2021-03-24 | Machado Patrick | Director | BUY | $9.92 | 10,000 | $99,196 | 88,182 | +12.8% |
| 2021-02-12 03:47 | 2021-02-09 | PATTERSON LEONE D | Officer - President and CFO | SELL | $14.10 | 12,533 | $176,718 | 97,955 | -11.3% |
| 2021-01-20 04:33 | 2021-01-15 | Machado Patrick | Director | BUY | $11.52 | 10,000 | $115,174 | 78,182 | +14.7% |
| 2021-01-20 04:32 | 2021-01-15 | Fischer Laurent | Director, Officer - CEO and Director | BUY | $11.53 | 8,600 | $99,191 | 16,292 | +111.8% |
| 2020-08-20 01:48 | 2020-08-17 | Soparkar Peter | Officer - Chief Legal Officer | BUY | $13.00 | 7,692 | $99,996 | 10,692 | +256.4% |
| 2020-08-20 01:45 | 2020-08-17 | Fischer Laurent | Director, Officer - CEO and Director | BUY | $13.00 | 7,692 | $99,996 | 7,692 | +100.0% |
| 2020-07-23 04:44 | 2020-07-20 | Gasmi Mehdi | Director | OPT+S | $17.60 | 5,000 | $87,978 | 274,442 | 0.0% |
| 2020-06-24 01:58 | 2020-06-22 | Gasmi Mehdi | Director | OPT+S | $25.06 | 23,605 | $591,617 | 274,442 | 0.0% |
| 2020-06-19 04:45 | 2020-06-17 | Gasmi Mehdi | Director | OPT+S | $25.01 | 11,395 | $285,031 | 274,442 | 0.0% |
| 2020-06-18 00:47 | 2020-06-16 | PATTERSON LEONE D | Officer - President | SELL | $24.68 | 13,171 | $325,060 | 110,488 | -10.7% |
| 2020-06-18 00:14 | 2020-06-15 | Gasmi Mehdi | Director | OPT+S | $21.86 | 10,000 | $218,627 | 274,442 | 0.0% |
| 2020-05-23 01:55 | 2020-05-20 | Gasmi Mehdi | Director | OPT+S | $20.02 | 5,000 | $100,078 | 274,442 | 0.0% |
How to Interpret $ADVM Trades
Not every insider transaction in Adverum Biotechnologies, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ADVM shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for ADVM
Insider activity data for Adverum Biotechnologies, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ADVM, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.